A recent study published in the British Medical Journal evaluated long-term symptoms and outcomes associated with post-coronavirus disease 2019 (COVID-19) condition.

Around 20% to 30% of non-vaccinated individuals suffer from the post-COVID-19 condition. Multiple studies investigating the long-term outcomes of the post-COVID-19 condition have reported that 22% to 75% of affected individuals experienced symptoms longer than one year after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

Many such studies comprised specific populations, focused on certain dimensions of the condition, and did not include a prospective follow-up. Moreover, their generalizability could be limited across the spectrum of COVID-19 severity. As such, limited knowledge and the lack of consensus on the core outcome set of the post-COVID-19 condition have resulted in using different outcome measures in observational studies, impacting their comparability.

Study: Recovery and symptom trajectories up to two years after SARS-CoV-2 infection: population based, longitudinal cohort study. Image Credit: p.ill.i / ShutterstockStudy: Recovery and symptom trajectories up to two years after SARS-CoV-2 infection: population based, longitudinal cohort study. Image Credit: p.ill.i / Shutterstock

About the study

The present study comprehensively characterized the post-COVID-19 condition in the longitudinal population-based Zurich SARS-CoV-2 cohort. Adult residents of the Zurich canton, Switzerland, were eligible if they could follow study protocols. Subjects with a confirmed SARS-CoV-2 infection diagnosis between August 6, 2020, and January 19, 2021, were recruited. The comparator group included participants from another study without SARS-CoV-2 infection.

Data obtained from questionnaires were used for analysis. At baseline, the questionnaire captured data on sociodemographics, comorbidities, pre-infection health status, and acute infection. Follow-up questionnaires were administered at multiple time points after infection, which collected information on symptoms and mental and physical health.

The primary outcome was the relative health status at 6, 12, 18, and 24 months post-infection. The outcome was defined using self-reported recovery status and overall health status. Secondary outcomes were the prevalence and severity of symptoms. Self-perceived severity was evaluated using a five-point Likert scale and stratified into mild, moderate, and severe categories. Further, the team assessed the trajectories of symptoms and relative health status between six and 24 months.

Additional scale-based assessments were used to investigate adverse outcomes, such as fatigue, dyspnea, depression, anxiety, stress, and quality of life. Data after reinfection were not considered for analysis. The point prevalence and severity of symptoms and the relative health status were descriptively evaluated at follow-up. The characteristics of participants with different trajectories were compared. The excess risk of symptoms and adverse outcomes was assessed at six months.

Findings

Overall, 1106 individuals participated in the Zurich SARS-CoV-2 cohort. Of these, 788 completed the assessment at 24 months, and 776 completed all questionnaires between six and 24 months. Most participants were symptomatic (86%) during acute COVID-19 and 4.3% required hospitalization. Around 51.2% of participants were females, and 55.2% returned to normal health status in less than one month post-infection. However, nearly 23% of participants did not recover by six months post-infection.

Mild, moderate, and severe health impairment was observed in 16.2%, 3.6%, and 2.7% of participants, respectively. The proportion of participants reporting non-recovery declined over time and was 18.5% at 12 months and 17.2% at 24 months. More than 68% of participants reported continued recovery over time. By 24 months, 13.5% had improved or recovered, 5.2% had worsened health status, and 4.4% had stable health impairment. 

The prevalence of symptoms was similar at follow-up time points at around 51%. However, the prevalence of COVID-19-related symptoms declined from about 29% at six months to 18.1% at 24 months. Notably, most participants with COVID-19-related symptoms reported non-recovery at 24 months. The common symptoms were fatigue, dyspnea, post-exertional malaise, poor concentration or memory, and altered smell or taste.

The proportion of participants with adverse outcomes on scale-based assessments increased shortly after the infection and decreased from one month onwards. By 24 months, the proportion of participants with fatigue, dyspnea, depression, anxiety, and stress was 36.8%, 23.4%, 12.5%, 11.7%, and 7%, respectively. The prevalence of any symptom was higher in the Zurich SARS-CoV-2 cohort compared to non-infected subjects in the comparator group.

The excess risks among infected subjects relative to non-infected participants were the highest for altered smell or taste, post-exertional malaise, reduced memory or concentration, dyspnea, and fatigue. Further, more infected participants had anxiety symptoms at six months than non-infected subjects. There were no differences in the proportions of subjects with stress, depression, or other adverse outcomes.

Conclusions

In sum, around 18% of subjects infected with SARS-CoV-2 reported post-COVID-19 symptoms, and 17% did not attain their normal health status by 24 months after infection. Although many subjects recovered or improved over time, some had worsened health status or alternating courses. In addition, there was strong evidence that infected individuals had an excess risk of symptoms than non-infected subjects.

Source link

PRESS RELEASE

Published June 5, 2023

New York, The Oscillating Positive Expiratory Pressure Devices Market was valued at USD 125.7 million in 2021 and it is anticipated to grow further till USD 208.9 million by 2031, at a CAGR of 5.2% during the forecast period.

Global Oscillating Positive Expiratory Pressure Devices Market report from Global Insight Services is the single authoritative source of intelligence on Oscillating Positive Expiratory Pressure Devices Market. The report will provide you with analysis of impact of latest market disruptions such as Russia-Ukraine war and Covid-19 on the market. Report provides qualitative analysis of the market using various frameworks such as Porters’ and PESTLE analysis. Report includes in-depth segmentation and market size data by categories, product types, applications, and geographies. Report also includes comprehensive analysis of key issues, trends and drivers, restraints and challenges, competitive landscape, as well as recent events such as M&A activities in the market.

Request sample copy of this research study: www.globalinsightservices.com/request-sample/GIS10444/

The machines that are utilized to remove secretions from the airways are known as oscillating positive expiratory pressure (OPEP) devices. People with chronic respiratory conditions like COPD, cystic fibrosis, and chronic bronchitis among others can benefit from it. The gadget is used to remove excess mucus that these illnesses produce. It facilitates breathing and helps to relax the lungs’ walls.

Market Trends and Drivers

The rising incidence of cystic fibrosis and chronic obstructive pulmonary disease (COPD) is driving up demand for mucous clearing devices as OPEP devices. According to the World Health Organization (WHO), COPD exacerbations are significant occasions in the development of the disease, and the associated impairment and mortality is anticipated to raise demand for these OPEP devices globally throughout the projection period. Additionally, the innovative strategy used by major players in the development of devices and the rising use of OPEP devices among patients with respiratory disorders are to blame for the promising growth prospects.

Get Customized Report as Per Your Requirement: https://www.globalinsightservices.com/request-customization/GIS10444/

Global Oscillating Positive Expiratory Pressure Devices Market Segmentation

By Product Type

  • Face Mask PEP Devices
  • Mouthpiece PEP Devices
  • Bottle PEP Devices

By Indication

  • COPD & Asthma
  • Bronchitis
  • Cystic Fibrosis
  • Others

By End User

  • Hospital & Clinics
  • Ambulatory Surgical Centers
  • Others

Major Players in the Global Oscillating Positive Expiratory Pressure Devices Market

The major players studied in the global oscillating positive expiratory pressure devices market are AirPhysio, Allergan plc., D-R Burton Healthcare, Medica Holdings, LLC., Monaghan Medical Corporation, PARI GmbH, R. Cegla GmbH & Co. KG, Smiths Medical, Inc., and WyMedical Pty Ltd among others.

Purchase your copy now: www.globalinsightservices.com/checkout/single_user/GIS10444/

With Global Insight Services, you receive:

  • 10-year forecast to help you make strategic decisions
  • In-depth segmentation which can be customized as per your requirements
  • Free consultation with lead analyst of the report
  • Excel data pack included with all report purchases
  • Robust and transparent research methodology

New Report Published by Global Insight Services: www.globalinsightservices.com/reports/hydrogen-projects-database/

About Global Insight Services:

Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.

Contact Us:
Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: [email protected]
Phone: +1-833-761-1700

Source link

In a recent article published in The Lancet, researchers described the heterogeneous nature of long coronavirus disease (Long-COVID), focusing on its pulmonary and extrapulmonary sequelae. They reviewed pre-existing respiratory issues [e.g., lung fibrosis, asthma, and chronic obstructive pulmonary disease (COPD)] that possibly aggravate pulmonary sequelae of COVID-19 or affect its outcomes. Additionally, the discussed clinical care, rehabilitation, and non-pharmacological strategies for people affected by post-COVID-19 dyspnea, a type of persistent disabling breathlessness.

Study: Respiratory sequelae of COVID-19: pulmonary and extrapulmonary origins, and approaches to clinical care and rehabilitation. Image Credit: Lightspring / ShutterstockStudy: Respiratory sequelae of COVID-19: pulmonary and extrapulmonary origins, and approaches to clinical care and rehabilitation. Image Credit: Lightspring / Shutterstock

Background

The post-acute sequelae of COVID 2019 (COVID-19), or PASC, systematically affects multiple organs, especially people with chronic lung diseases like thromboembolic disease.

Multiple previous studies have described worsening of respiratory systems during PASC due to destabilizing of pre-existing symptoms or COVID-19-related effects, independent of the severity of acute illness; however, the exact mechanisms governing these changes remain unclear. 

Several published studies have also described, using a large dataset, the cluster of respiratory symptoms constituting PASC, for instance, erratic breathing, hyperventilation, and persistent cough. Perhaps, mechanisms like viral persistence, autoimmunity, and systemic inflammation, including activation of interferon (IFN) I and III and interleukin 6, contribute to the worsening of respiratory systems during PASC.

By March 2023, worldwide COVID-19 mortality had reduced from 101,600 deaths to 6,500 deaths per week. Also, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related hospital admissions have reduced drastically. Researchers have attributed these improvements, in part, to the increased availability of vaccines and treatments, such as IL-6 therapies. However, it remains critical to understand the long-term effects of COVID-19 on the respiratory system for studies focused on the post-COVID-19 landscape.

About the study

To this end, in the present study, researchers extensively searched databases, such as PubMed and CINAHL, using keywords like dysfunctional breathing, post-COVID fibrosis, fibrosis, and rehabilitation, to name a few.

Regarding post-COVID-19 conditions, they uncovered that the most prevalent symptoms were independent of the severity of acute illness. For instance, understanding the precise mechanisms that underlie symptoms of acute lung injury, the dominant insult in severe acute COVID-19 patients requiring mechanical ventilation, in contrast to any post-COVID-19 sequelae, requires proper assessments and targeted interventions.

The team identified a meta-analysis that covered 54 studies and two medical records that discussed respiratory symptoms as an important cluster alongside fatigue and cognitive problems post-long COVID. In contrast, another study defined a positive correlation between the burden of symptoms and their severity with all the symptoms combined.

Extrapulmonary and pulmonary sequelae of COVID-19

In this study, researchers discussed the incidence and mechanisms of pulmonary fibrosis, pulmonary emboli, and microvascular thrombi, COPD, reduced exercise tolerance, and frailty after COVID-19. In addition, they highlighted studies discussing all these features of long COVID to bring attention to the fact that these contribute to breathlessness and breathing pattern disorders, hence, need attention when devising therapeutic and rehabilitative strategies.

Here it is noteworthy that conventional measures of lung function cannot consistently predict breathlessness. It is a complex condition, which, if pathologically triggered, does not necessarily improve after treatment with bronchodilators. Thus, treatment approaches for breathlessness should be guided by an extensive assessment that covers routine spirometry.

The largest cohort study conducted among 1,733 people discharged from the hospital after COVID-19 recovery performed lung function tests in 349 participants six months post-discharge. It was biased toward adults with clinical symptoms of pulmonary issues. In addition, it should cover Dyspnoea Profile questionnaires that explore the multidimensional components of breathlessness. Clinicians must also consider cardiopulmonary exercise testing and more complex investigations, such as magnetic resonance imaging (MRI) in cases of diagnostic uncertainties related to breathlessness

In post-COVID-19 conditions, cardiopulmonary exercise testing identified dysfunctional breathing or an erratic breathing pattern in the absence of a respiratory limitation or impaired oxygen delivery and reported a lower peak oxygen uptake in individuals with persistent breathlessness compared with those who had a full recovery after COVID-19.

Small cohort studies documented altered breathing patterns in ~20% of people admitted to hospitals with acute COVID-19, and those not admitted to hospital were referred to specialist follow-up clinics. They attributed aberrant breathing patterns to changes in lung function and effects of sedation and mechanical ventilation on respiratory centers, etc.

The Nijmegen Questionnaire specifically accessed hyperventilation syndrome, and the Breathing Pattern Assessment Tool (BPAT) accessed all breathing pattern disorders with high sensitivity and specificity.

Likewise, mechanistic similarities between COVID-19-related pneumonia and idiopathic pulmonary fibrosis (IPF), raise the possibility of a potential global burden of long-term fibrosis arising post-COVID-19.

At present, rehabilitation programs for people with post-COVID-19 conditions are highly heterogeneous, but they should cover aerobic and resistance exercises and spread awareness on symptom management. A recent systematic review showed they improved dyspnoea, physical function, and QoL. However, patients should be selected per symptom profiles, and further research should focus on high-quality evidence, particularly for people not admitted to hospital for COVID-19.

Research evaluating the effectiveness of non-pharmacological interventions is ongoing. However, respiratory and rehabilitation specialists should be at the core of integrated multidisciplinary teams offering support to patients with post-COVID-19 conditions. Most importantly, these teams should use therapeutic and rehabilitative strategies tailored to each patient's symptom profiles and specific needs to ensure they give culturally appropriate, equitable access to the diverse set of affected populations.

Conclusions

Like other critical illnesses, severe COVID-19 leaves patients with long-term morbidity that affects their quality of life (QoL) and physical and mental well-being. As well-recognized, symptoms-like brain fog and cognitive deficits are common in patients with long COVID. These manifestations might be related to the disease, its treatment, or both; notably, doctors administer such treatments in the intensive care unit (ICU) to complement life-support therapies.

In the future, studies should target characterizing the long-term complications of pulmonary and extrapulmonary sequelae of COVID-19 in-depth, e.g., its mechanisms of causing insult. Further, these studies should determine optimal diagnostic and management approaches for this debilitating condition to improve outcomes in this population.

Other future research priorities should be as follows:

i) identifying mechanisms governing reduced asthma and COPD control after COVID-19

ii) extrapulmonary complications that give rise to or worsen breathlessness after COVID-19

iii) diagnostic modality for detection of post-COVID-19 pulmonary vascular disease

iv) strategies to prevent, mitigate, and treat pulmonary fibrosis

v) mechanisms driving symptoms of breathlessness post-COVID-19 and rehabilitation or breathing exercises that effectively reduce it.

Journal reference:

Source link

Typically, it’s late summer and into autumn when you start thinking about boosting your immune system. With colder weather, we’re expecting a surge of upper respiratory infections (URIs), such as the common cold and the annual flu season. We expect to spend more time indoors, in closer contact with more people, but every cough and sneeze can spread infectious respiratory droplets over alarming distances. 

Since COVID, however, “typical” virus prep is no more. Viruses, disease testing methods, immunizations, and disease-mitigation practices have all changed. It makes sense to optimize immune health year-round. Along with social distancing, masks, and vaccinations, is there a role for dietary supplements in infectious disease prevention or management?

Zinc, vitamin C, and vitamin D are popular supplements for people seeking to bolster their immune systems, but are they really helping? Let’s take a look at 10 of the common beliefs about respiratory infections and how to treat them — to decide which are fact and which are fiction.

1. Zinc supplements taken within 24 hours of the onset of symptoms of the common cold can decrease the duration of illness.

Fact. A recent analysis of multiple studies on the use of zinc lozenges or oral sprays for cold symptoms found that they shortened the duration of illness by about two days.

Zinc is important for the generation of T cells, a type of immune cell active against cells infected with bacteria and viruses. It also affects the functions of cells that line the respiratory tract — the first line of defense against germs causing respiratory infections.

2. Zinc supplements taken within 24 hours of the onset of COVID-19 symptoms will decrease the severity of an individual’s illness.

Fiction. A panel at the National Institutes of Health (NIH) stated:

  • There is insufficient evidence for the panel to recommend either for or against the use of zinc for the treatment of COVID-19.
  • The panel recommends against using zinc supplementation above the recommended dietary allowance (i.e., zinc 11 mg daily for men, zinc 8 mg daily for nonpregnant women) for the prevention of COVID-19.
Zinc supplement tablets on a plate
(Photo by Fida Olga on Shutterstock)

3. Zinc supplements should be ingested with a meal for maximum absorption.

Fiction. Zinc supplementation as part of a meal can significantly reduce zinc absorption when compared to water-based solutions of zinc. Dietary phytate, a natural substance in corn, rice, and cereals binds to zinc, severely restricting its absorption in the gut. Diets high in phytate can result in zinc deficiency, even with adequate zinc intake.

People with a good diet get plenty of zinc from meat, beans, lentils, seafood, and whole grains. They are unlikely to need zinc supplements.

4. Aging increases your susceptibility to zinc deficiency.

Fact. Elderly individuals are more susceptible to zinc deficiency than younger individuals, increasing their likelihood of acquiring life-threatening viral infections.

Zinc can interact or interfere with some medications and other supplements. Check with a physician before taking supplements.

5. Vitamin C reduces the incidence of the common cold in community populations.

Fiction. Vitamin C does not reduce the incidence of the common cold in community populations. Like zinc, however, vitamin C shortened the duration of symptoms.

Vitamin C contributes to the health of the immune system by triggering neutrophils and macrophages (types of white blood cells with immune functions) to fight infection and reduce inflammation. Macrophages kill and ingest germs, then clear away cellular debris.

6. Vitamin C supplements can help COVID-19 patients avoid hospitalization.

Fiction.  A panel at the NIH stated:

  • There is insufficient evidence for the Panel to recommend either for or against the use of vitamin C for the treatment of COVID-19 in non-hospitalized patients. Because patients who are not critically ill with COVID-19 are less likely to experience severe inflammation, the role of vitamin C in this setting is unknown.

The position of the panel is the same for hospitalized patients with COVID-19.

7. Consuming excessive vitamin C can cause kidney stones.

Fact. An article in JAMA Internal Medicine reported a connection between kidney stone formation and use of vitamin C supplements. Men who used supplements were twice as likely to experience kidney stones as men who did not use supplements. Use of a multivitamin did not increase the risk of kidney stones.

The vitamin C requirement for men is 90 mg per day, and 75 mg per day for women.

Foods High in vitamin C on a wooden board.
(© bit24 – stock.adobe.com)

8. Low vitamin D levels have been linked to increased risk for respiratory infections.

Fact. One study with almost 19,000 individuals found an inverse relationship between blood levels of vitamin D and upper respiratory infections (URI’s) such as the common cold. The lower the level of vitamin D, the greater the risk of developing a URI. 

Another study found that, like zinc and vitamin C, vitamin D supplements may shorten the duration of the symptoms associated with a URI.

9. Low blood levels of vitamin D increase susceptibility to COVID-19 infection.

Fiction. Currently, data are insufficient to support a recommendation for or against the use of vitamin D supplementation to prevent or manage COVID-19. Some evidence, however, suggests that vitamin D supplementation helps prevent respiratory tract infections, particularly in people with 25(OH)D (vitamin D) levels less than 25 nmol/L (10 ng/m). Scientists are studying whether vitamin D might also be helpful for preventing or treating COVID-19.

Vitamin D foods
(© Leigh Prather – stock.adobe.com)

10. Vitamin D supplements can adversely interact with some medications.

Fact. Vitamin D supplements may interact with some medicines. These are several examples:

  • Orlistat (Xenical®) is a weight-loss drug. It can decrease the amount of vitamin D your body absorbs from food and supplements.
  • Cholesterol-lowering statins might not work as well if you take high-dose vitamin D supplements. This includes atorvastatin (Lipitor®), lovastatin (Altoprev®), and simvastatin (FloLipid™).
  • Steroids, such as prednisone (Deltasone®) can lower your blood levels of vitamin D.
  • Thiazide diuretics (Hygroton®) could raise your blood calcium level too high if you take vitamin D supplements.

Tell your doctor, pharmacist, and any other healthcare providers about any dietary supplements and prescription or over-the-counter medicines you take. They can tell you if the dietary supplements might interact with your medicines. They can also explain whether the medicines you take might interfere with how your body absorbs or uses other nutrients.

While many of the studies are inconclusive, what you can take from this article with conviction is that, for your good health, eat a large variety of foods: proteins, complex carbohydrates, and healthy fats. Try to get your nutrients from fresh and unprocessed foods as much as you can. Exercise. Sleep. Build relationships. Play. Give. Keep reading.

YouTube video

Source link

TANZANIA has recorded 64 new cases of the Covid-19, increasing from 45 cases recorded four weeks ago, according to the Ministry for Health data update.

The statistics recorded from 22 April – 26 May this year, represents a 45 per cent increase in new cases during the period in which no disease-related deaths or patient admissions were reported.

The government has continued to enhance the control of Covid-19 in the nation, according to a statement released by the ministry on Tuesday, and it has also kept the public informed about the disease’s trend.

“Among other things, the government has carried on with Covid-19 vaccination services in the country to enable citizens to get total immunity and thereby prevent serious illness and even death when a person is infected with the virus,” the statement reads in part.

As of May 26, this year a total of 32,763,672 people, which is equal to 106.6 per cent of the target population (people aged 18 years and older) had received a full dose of Covid-19 vaccine.

However, this is equal to 55 per cent of 59,851,347 Tanzanians living in mainland. The Ministry states that it is still closely observing the Covid-19 situation in the nation and around the world, in addition to informing the public and implementing new control measures.

It also exhorts anyone experiencing respiratory system disease symptoms, such as fever, flu, cough, body fatigue, joint discomfort, headache, sore throat, or breathing difficulties, to seek medical attention as soon as possible so they can be evaluated and provided the proper care.

The ministry also urges people to get full doses of the Covid-19 vaccination, use masks when they have flu-like symptoms or a cough, and avoid crowded places when possible if they want to protect themselves from Covid-19 and other dangerous diseases.

Other precautions include routine hand washing with soap and running water, strengthening the body through exercise and a healthy diet, developing a habit of visiting medical facilities when feeling unwell, and informing authorities via the toll-free number 199 about the presence of those exhibiting disease symptoms in the neighbourhood.

Source link

As cases of COVID-19, flu and respiratory syncytial virus (RSV) were winding down across the United States, infections of another respiratory virus, called human metapneumovirus (HMPV), were picking up during spring and drawing concern as many people had not known about it.

Discovered in 2001, HMPV is in the Pneumoviridae family along with RSV. Broader use of molecular diagnostic testing has increased identification and awareness of HMPV as an important cause of upper and lower respiratory infection, according to the U.S. Centers for Disease Control and Prevention (CDC).

Cases of HMPV spiked in the United States this spring, according to the CDC’s respiratory virus surveillance system. The percent of tests positive for HMPV surged to 17.5 percent for antigen tests and 9.6 percent for PCR tests at the end of March.

At its peak in mid-March, nearly 11 percent of tested specimens were positive for HMPV, a number that was about 36 percent higher than the average, pre-pandemic seasonal peak of 7 percent test positivity, according to a CNN report.

It filled hospital intensive care units with young children and seniors who are the most vulnerable to these infections.

HMPV can cause upper and lower respiratory disease in people of all ages, especially among young children, older adults, and people with weakened immune systems, according to the CDC.

Surveillance data from the CDC’s the National Respiratory and Enteric Virus Surveillance System shows HMPV to be most active during late winter and spring in temperate climates.

Symptoms commonly associated with HMPV include cough, fever, nasal congestion, and shortness of breath, according to the CDC.

Unlike COVID-19 and the flu, there is no vaccine for HMPV or antiviral drugs to treat it. Instead, doctors care for seriously ill people by tending to their symptoms.

But there is no need to be too concerned about HMPV, a leading epidemiologist told Xinhua.

“The transmission mode, prevention methods, symptoms, and treatment of this virus are similar to influenza. So there is no need to worry too much except for the elderly people, the immunocompromised population and other high-risk groups,” Zhang Zuofeng, professor and chair of the Department of Epidemiology at the University of California, Los Angeles, told Xinhua on Friday.

Source link

Oxify promises a range of health benefits through its treatments at Clifton Moor <i>(Image: Pic supplied)</i>

Oxify promises a range of health benefits through its treatments at Clifton Moor (Image: Pic supplied)

York residents are finding new oxygen treatments a breath of fresh air.

Since Oxify opened its fourth treatment centre on Clifton Moor last month, people have enjoyed £10 taster sessions and more.

Father and daughter team Michael Todd and Sarah Todd from Retford, Nottinghamshire, opened their first centre there in 2021.

Oxify’s treatment is non-invasive and involves breathing oxygen in a pressurised environment. This allows the body to absorb up to 16 times more oxygen to benefit the body’s cells. It claims to an effective treatment for stress relief, skin rejuvenation, chronic fatigue, sports recovery and the symptoms of Long Covid, amongst other issues.

Michael had previously worked in printing for 30 years, running his own business, and Sarah had a career in hospitality management.

Oxify opens at Clifton Moor with new treatments

In late 2020, Michael read a magazine article entitled ‘Who Wants to Live Forever’ which cited research at Tel Aviv University showed Hyberbaric Oxygen Therapy (HbOT) can reverse cell aging.

Michael told the Press: “I was intrigued and decided to find out more. The more I researched the more excited I was about the huge therapeutic benefits offered by HbOT.”

He bought a chamber and installed it in Retford in 2021, creating the Oxify business.

Michael continued: “The excitement of HbOT is that, without drugs or surgical intervention, it provides a lasting remedy for many debilitating and intractable ailments.

“The rejuvenation of cells through the supply of enriched oxygen means that the range of conditions it can help is exceptionally wide ranging.  The market for the Therapy is huge from sportsmen preparing or recovering through to sufferers from Long Covid and Chronic Fatigue.“

Since opening Retford, ‘huge demand’ led to new centres in Leeds, Manchester and now Kettlestring Lane.

Freeklime 'bouldering' centre opens today at Clifton Moor

“We are on a mission to help as many people as we can and to make HbOT well known and recognised as a huge benefit to unwell and healthy people alike,” he explained.

“Our biggest challenge is to educate. Whilst the benefits of HbOT are widely known about in other countries it is relatively unknown in the UK. We are determined to change that!!”

Over the next year, Oxify plans to offer shares through Crowdfunding. It also plans to open 20 more centres over the next 18 months.

Since opening in York on May 9, Oxify reports consistent bookings.

Michael said: “Our taster sessions for those new to HbOT have been brisk - which shows us that the community in York and the wider York area are open to HbOT and enthusiastic about this innovative and non-invasive treatment, and we have welcomed new customers to our York centre with repeat bookings already.

“It's been a real pleasure to work with our York staff and we look forward to growing our number of centres to reach more and more people."

For details and to book, go to: www.oxify.co.uk

Source link

Parents are advised to look out for signs of breathing problems in young children over winter, with a report highlighting the deadly risks from a mostly unknown seasonal virus.

The report found RSV, or respiratory syncytial virus, is responsible for the hospitalisation of about 12,000 babies under 12 months each year.

That number climbs to over 15,000 for children under five, which is eight times higher than the numbers hospitalised for the flu.

The virus is relatively unknown within the community, with Australia's first RSV Awareness week launched on June 4.

Children who contract the virus can suffer long term health complications including allergies and asthma.

In infants, symptoms include a runny nose, coughing, sneezing, wheezing, loss of appetite, lethargy and irritability.

The report, funded by pharmaceutical giant Sanofi, found low levels of awareness of the virus within the community, despite the dangers.

Healthcare advisory company Evohealth was involved in the report, with managing director Renae Beardmore saying growing awareness of the virus is showing the scale of its impact on Australian children.

She said while most children will contract the virus by the age of two, some will suffer complications such as bronchiolitis and pneumonia.

"This is a virus that often went undiagnosed due to lack of awareness, monitoring and reporting, which has recently changed," she said.

"Now that we are starting to understand the scale of the RSV in Australia, it's time to act to reduce the burden of the virus on children, parents and hospitals."

The report found the common and unpredictable virus is costing the healthcare system about $200 million a year.

Last month, the Therapeutic Goods Administration gave the green light to a newly approved nasal swab able to diagnose COVID-19, influenza and RSV within 15 minutes.

Channel Nine broadcaster Karl Stefanovic and his wife Jasmine are involved in the RSV awareness week campaign, after their young daughter Harper suffered complications from the virus last winter.

Stefanovic became emotional on air last year when he described their fear as their two-year old daughter was hospitalised.

The Immunisation Foundation Australia is hopeful RSV will soon become a vaccine-preventable illness, with founder Catherine Hughes's daughter also impacted by the virus.

"It's important that caregivers know the signs that may indicate severe disease, trust their gut, and seek medical attention when it's needed," she said.

Source link

CONNECTICUT — Cases of a little-known respiratory illness that is especially dangerous for young children — human metapneumovirus, or HMPV — and mimics the symptoms of other common respiratory diseases spiked this spring in the Northeast, according to Centers for Disease Control and Prevention health data.

A regional breakdown of HMPV cases shows nearly a 50 percent positivity rate among those antigen tested in Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island and Vermont around the second and third weeks in April. That's up about 25 percent from similar testing done a month earlier.

The symptoms of the lower lung infection include a deep cough, fever, runny nose, sore throat and shortness of breath, which are also symptoms of RSV, influenza and COVID-19. As cases of those illnesses began to subside, HMPV was just getting started in many parts of the country, according to the CDC data.

At the mid-March peak of HMPV, nearly 11 percent of specimen tests nationwide were positive. That’s about 36 percent higher than the average, pre-pandemic seasonal peak of 7 percent HMPV test positivity.

Viruses are responsible for a range of respiratory infections, from the common cold to severe bronchitis and pneumonia. With improvements in molecular testing, more viruses have been detected, including pneumovirus isolated two decades ago by Dutch scientists in children with respiratory illnesses.

Medical experts don’t know the full burden of HMPV because testing is rarely done until the patient has to be hospitalized. Dr. John Williams, a pediatrician at the University of Pittsburgh, told CNN that HMPV cases are at least equal to RSV and influenza.

The CDC recommends that physicians and clinics test for it regularly.

Respiratory infections are the leading cause of death in children under 5 worldwide and a major reason for hospitalizations of young children in developed countries. According to the CDC, HMPV also poses risks for older adults and people with weakened immune systems.

According to a 2020 study in The Lancet Global Health journal, an estimated 14 million children under 5 worldwide had HMPV infections in 2018, resulting in 600,000 hospitalizations and more than 16,000 deaths.

Several pharmaceutical companies are working on vaccines, including COVID-19 vaccine maker Moderna, which just completed a clinical trial testing an mRNA vaccine against HMPV.

Source link

FRIDAY, June 2, 2023 (HealthDay News) -- A group of symptoms has been identified that can define postacute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PASC), according to a study published online May 25 in the Journal of the American Medical Association.

Tanayott Thaweethai, Ph.D., from Massachusetts General Hospital in Boston, and colleagues used self-reported symptoms to develop a definition of PASC and describe PASC frequencies across cohorts in a prospective observational cohort study of adults with and without SARS-CoV-2 infection at 85 sites located in 33 states, Washington, D.C., and Puerto Rico. A total of 9,764 participants met the selection criteria (8,646 infected; 1,118 uninfected).

The researchers found that for 37 symptoms, the adjusted odds ratios were 1.5 or greater for infected versus uninfected participants. Postexertional malaise, fatigue, brain fog, dizziness, gastrointestinal symptoms, palpitations, changes in sexual desire or capacity, loss of or change in smell or taste, thirst, chronic cough, chest pain, and abnormal movements were included as symptoms contributing to the PASC score. Overall, 10 percent of the 2,231 participants first infected on or after Dec. 1, 2021, and enrolled within 30 days of infection were PASC-positive at six months.

"This study is an important step toward defining long COVID beyond any one individual symptom," a coauthor said in a statement. "This research definition -- which may evolve over time -- will serve as a foundation for scientific discovery and treatment design."

Several authors disclosed ties to the pharmaceutical industry.

Abstract/Full Text

Editorial



Source link

Now that COVID-19 is no longer an active emergency, post–COVID-19 condition, or “long COVID,” has become the central concern regarding the SARS-CoV-2 virus.

Approximately 20-30% of individuals who contract COVID-19 will experience prolonged symptoms 3-6 months after acute infection; symptom severity may range from inconvenient to insurmountable.

We are still living in the shadow of COVID-19, but some individuals who were infected early in the pandemic can be evaluated to determine longer term symptoms and health outcomes of long COVID. One study, recently published in The BMJ, aimed to comprehensively characterize post–COVID-19 condition in a population-based, longitudinal cohort of individuals who had previously contracted COVID-19.

The investigators described patterns of recovery and symptom persistence over a 2-year period, seeking to determine the risk of related symptoms by comparing their prevalence in a general population cohort who were never infected with COVID-19. Utilizing the ongoing population-based, prospective Zurich SARS-CoV-2 Cohort study, the investigators recruited individuals with a confirmed COVID-19 diagnosis. Eligible participants were 18 years and older, resided in Zurich, and were sufficient in the German language.

From August 6, 2020-January 19, 2021, participants who PCR tested positive for COVID-19 were enrolled in the study. The study patients had all been infected with the earliest iteration of COVID-19, the wildtype Wuhan-Hu-1 strain. All individuals contracted COVID-19 before vaccines were made available.

The primary study outcome was the overall relative health status of participants at 6, 12, 18, and 24 months after infection. Participants were asked whether they had recovered compared to their usual health before COVID-19, and their overall health was evaluated using the EuroQol visual analogue scale. Secondary outcomes included the prevalence and severity of 23 long COVID symptoms.

A total of 1106 Zurich SARS-CoV-2 Cohort patients consented to participate in this study, with 72% (n = 788) completing the 24-month assessment. Of 1106 study patients, 51.2% were female. During acute COVID-19 infection, 86.0% (n = 951) were symptomatic and 4.3% (48) were hospitalized.

Overall, 55.3% of participants reported returning to their normal health status within a month of contracting COVID-19. Within 1-3 months, another 17.6% reported they had recovered. At 6 months, 22.9% of participants had not yet recovered. Among them, 16.2% had mild symptoms, 3.6% had moderate symptoms, and 2.7% had severe health impairment.

At 12 months after acute infection, the participants reporting nonrecovery was reduced to 18.5%. After 18 months, this fell to 17.2%. Severity of health impairment also decreased at 24 months after acute infection, with 10.4% reporting mild symptoms, 3.9% reported moderate symptoms, and 1.9% reported severe impairment.

According to self-reported health status over time, 68.4% of participants had a continued recovery and 13.5% had an overall improvement. However, 5.2% of the study patients experienced a worsening of health status, with 4.4% reported alternating periods of recovery and health impairment.

After 24 months, 1 in 6 of the unvaccinated participants reported they were still experiencing health repercussions from COVID-19 infection. The investigators confirmed symptom prevalence with a cohort of individuals who had never contracted COVID-19. The highest symptoms reported were altered taste or smell (9.8%), post-exertional malaise (9.4%), fatigue (5.4%), dyspnea (7.8%), reduced concentration (8.3%), and memory impairment (5.7%).

The investigators noted their finding that 18% of unvaccinated individuals had post–COVID-19 condition up to 2 years after infection aligns with prior research. Symptom severity and health impairment did reduce over time, but further study is needed to establish effective interventions to combat long COVID.

Source link



This past Sunday in the church I serve, we had a conversation about the celebration of Pentecost, which signals for us the birth of the church as God sent the Spirit in dramatic fashion.

In the book of Acts, Luke tells us that, when that huge Festival had come, the disciples were all together in one place in the city of Jerusalem. And, suddenly, from heaven there came a sound like the rush of a violent wind, and it filled the entire house where they were sitting.

So, naturally, our Pentecost conversation was swept up in images of crowded rooms and wind and breath.

Did you know the word “conspire” means to breathe together? Take a breath. Now blow it out again. There! If you are sharing space with another person, you have just launched a conspiracy. You can hear the word “spirit” in there too — to conspire — to be filled with the same spirit, to be enlivened by the same wind.

That is why the word appeals to me today. And, in my thinking, the word “conspiracy” badly needs redemption after a few years of its association with malevolent intent and misinformation.

What happens between us when believers come together to worship God is that the Holy Spirit swoops in and out among us, knitting us together and empowering us through the songs we sing, the prayers we offer, the breath we breathe.

It can happen with two people and it can happen with 200. It can scare us or comfort us, confuse us or clarify things for us, but, as far as I can tell, the Holy Spirit never bullies. We are always free to choose whether or how we will respond.

Of all the ways we talk about God, I suppose the Holy Spirit presents the biggest challenge.

Most of us can at least begin to find words for the other two: God the Father, creator of Heaven and Earth, who makes the sun blaze and the rain fall, whose creation reflects God’s nature, majesty and power. God the Son, who became human like us, we describe in the roles of savior, redeemer, teacher, helper, and friend.

But how would you describe God the Holy Spirit to a 5-year-old?

Even Jesus had a hard time with that one. “The Spirit blows where it chooses,” he said in John’s gospel, “and you hear the sound of it, but you do not know where it comes from or where it goes (3:8).”

And, if we have a difficult time talking about WHO the Holy Spirit is, we have an equally difficult time talking about our personal experiences of the Spirit.

Many people I know can’t say if they have ever really had an experience of God. At least they can’t articulate how they recognize it. But, when people start talking about their lives, it seems clear to me they have.

They did not have a name for it, so they wrote it off to coincidence or hormones. Just in case you have had some things happen to you that you do not have a name for, I want to suggest at least one way I believe the Holy Spirit blows into our lives.

One breeze of the Spirit is to give people a way back into relationships. Maybe that has happened to you. You are estranged from someone you really care about — because of something you said or did or perhaps you were the one offended — it really does not matter.

The point is, you are tired of it, so you start plotting ways to get through. You draft letters, rehearse phone calls, only none of them sounds right.

You are still hanging on to your hurt or your anger. Then, one day, for no apparent reason, something inside of you says, “Now.” You grab the phone. The person says, “Hello?” And the rest is history.

On both ends, hearts open and the right words come out. A reunion gets underway. You can call that anything you want, but I prefer to call it a breath of God’s Spirit.

I think that’s why the past three years with COVID-19, the threatening respiratory virus that was transmitted by breathing — taking respiration with others present — was culturally and socially so devastating. It separated us. It made us keep a “safe” distance and mask up. And, for all the blessings of Zoom and livestreaming, THERE IS NO SUBSTITUTE for gathering and embracing and singing and learning together in actual sanctuaries and classrooms with real people present.

Pentecost hits a nerve for post-pandemic Christians. It’s made us quite aware of just how much we need to breathe together. In the time of the pandemic, breathing together was exactly what we avoided. We didn’t want to infect anyone else or be infected.

Yet the quarantine, as it dragged on — along with all of its financial, psychological, social consequences — the isolation costs us something spiritually, too. We needed Conspiracy — to breathe together — and we were denied it.

So take a breath. Now, just keep breathing. This is God’s moment-by-moment gift to us. We can call it air or we can call it Spirit or we might name it by its Hebrew word, “Ruach.”

Life is a real, live conspiracy where we breathe in and breathe out the Spirit of God — within community, singing, praising, serving, praying. Happy Pentecost.

Warren Hoffman is a 43 year veteran of pastoral ministry and considers himself a native of Alpena. He is married to his ministry partner and beloved, Laura Hoffman.



Today's breaking news and more in your inbox








Source link

The Sunday Mail

As cases of Covid-19, flu and respiratory syncytial virus (RSV) were winding down across the United States, infections of another respiratory virus, called human metapneumovirus (HMPV), were picking up during spring and drawing concern as many people had not known about it.

Discovered in 2001, HMPV is in the Pneumoviridae family along with RSV. Broader use of molecular diagnostic testing has increased identification and awareness of HMPV as an important cause of upper and lower respiratory infection, according to the US Centers for Disease Control and Prevention (CDC).

Cases of HMPV spiked in the United States this spring, according to the CDC’s respiratory virus surveillance system. The percent of tests positive for HMPV surged to 17,5 percent for antigen tests and 9,6 percent for PCR tests at the end of March.

At its peak in mid-March, nearly 11 percent of tested specimens were positive for HMPV, a number that was about 36 percent higher than the average, pre-pandemic seasonal peak of 7 percent test positivity, according to a CNN report.

It filled hospital intensive care units with young children and seniors who are the most vulnerable to these infections.

HMPV can cause upper and lower respiratory disease in people of all ages, especially among young children, older adults, and people with weakened immune systems, according to the CDC.

Surveillance data from the CDC’s the National Respiratory and Enteric Virus Surveillance System shows HMPV to be most active during late winter and spring in temperate climates.

Symptoms commonly associated with HMPV include cough, fever, nasal congestion, and shortness of breath, according to the CDC.

Unlike Covid-19 and the flu, there is no vaccine for HMPV or antiviral drugs to treat it. Instead, doctors care for seriously ill people by tending to their symptoms.

But there is no need to be too concerned about HMPV, a leading epidemiologist told Xinhua.

“The transmission mode, prevention methods, symptoms, and treatment of this virus are similar to influenza. So there is no need to worry too much except for the elderly people, the immunocompromised population and other high-risk groups,” Zhang Zuofeng, professor and chair of the Department of Epidemiology at the University of California, Los Angeles, told Xinhua on Friday. – Xinhua

Source link

The province reported 21 COVID-19-related hospital admissions for the second consecutive week in its most recent respiratory illness surveillance data. 

There were five intensive care unit admissions related to COVID-19 reported for the week of May 21-27 in data released Friday, which is two more than the previous report, which covered the week of May 14-20.

There has been 405 deaths due to COVID-19 this year, the most recent report said, the same number reported last week.

The test positivity rate was similar to last week's report, moving down slightly to 10.1 per cent from 10.2 per cent. 

There were 59 cases of COVID-19 detected, which is undercount because the province no longer does broad testing nor does it include home-based test results in its tallies. 

There were two COVID-19 outbreaks in long-term-care facilities reported for the week, and a total of 260 in 2023. There has been a total of 108 COVID-19 outbreaks in hospitals this year.

Influenza rates remain stable, with three new cases of Influenza A and four new cases of Influenza B. 

Respiratory syncytial virus, or RSV, activity also remained stable, with one new case detected and a positivity rate of 0.1 per cent.

Source link

Travelers walk through terminals at Ronald Reagan Washington National Airport in Arlington, Virginia, the United States, April 14, 2022.(Photo by Ting Shen/Xinhua)

As cases of COVID-19, flu and respiratory syncytial virus (RSV) were winding down across the United States, infections of another respiratory virus, called human metapneumovirus (HMPV), were picking up during spring and drawing concern as many people had not known about it.

Discovered in 2001, HMPV is in the Pneumoviridae family along with RSV. Broader use of molecular diagnostic testing has increased identification and awareness of HMPV as an important cause of upper and lower respiratory infection, according to the U.S. Centers for Disease Control and Prevention (CDC).

Cases of HMPV spiked in the United States this spring, according to the CDC's respiratory virus surveillance system. The percent of tests positive for HMPV surged to 17.5 percent for antigen tests and 9.6 percent for PCR tests at the end of March.

At its peak in mid-March, nearly 11 percent of tested specimens were positive for HMPV, a number that was about 36 percent higher than the average, pre-pandemic seasonal peak of 7 percent test positivity, according to a CNN report.

It filled hospital intensive care units with young children and seniors who are the most vulnerable to these infections.

HMPV can cause upper and lower respiratory disease in people of all ages, especially among young children, older adults, and people with weakened immune systems, according to the CDC.

Surveillance data from the CDC's the National Respiratory and Enteric Virus Surveillance System shows HMPV to be most active during late winter and spring in temperate climates.

Symptoms commonly associated with HMPV include cough, fever, nasal congestion, and shortness of breath, according to the CDC.

Unlike COVID-19 and the flu, there is no vaccine for HMPV or antiviral drugs to treat it. Instead, doctors care for seriously ill people by tending to their symptoms.

But there is no need to be too concerned about HMPV, a leading epidemiologist told Xinhua.

"The transmission mode, prevention methods, symptoms, and treatment of this virus are similar to influenza. So there is no need to worry too much except for the elderly people, the immunocompromised population and other high-risk groups," Zhang Zuofeng, professor and chair of the Department of Epidemiology at the University of California, Los Angeles, told Xinhua on Friday. 

Source link

DUBLIN, June 2, 2023 /PRNewswire/ -- The "Inhaled Nitric Oxide Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023-28)" report has been added to  ResearchAndMarkets.com's offering.

Research and Markets Logo

Research and Markets Logo

The inhaled nitric oxide market is expected to register a CAGR of nearly 4.6% during the forecast period.

Companies Mentioned 

  • Air Liquide Healthcare

  • BOC Healthcare

  • Matheson Tri-Gas Inc.

  • Merck KGaA

  • Mallinckrodt Pharmaceuticals (Novoteris)

  • Nu-Med Plus Inc.

  • Perma Pure LLC

  • Praxair Distribution Inc.

  • HALMA PLC

  • LINDE PLC

  • Bellerophan Therapeutics Inc.

Inhaled Nitric Oxide Market Trends

The Asthma and COPD Segment is Expected to Witness a Significant Growth Over the Forecast Period.

Asthma and COPD are considered among the most common respiratory diseases affecting the population and life-threatening conditions affecting patients' regular breathing. Asthma is a persistent condition that stretches and narrows the air passages of the lungs, causing constant assaults of breathlessness, bronchospasm, and reversible obstruction of airflow.

A large rise in the consumption of cigarettes contributes to asthma and COPD symptoms. In addition, the advancement in industrialization has also contributed to an increase in the number of cases of asthma and COPD, which, over the forecast period, may drive the demand for inhaled nitric oxide.

An article published in the journal JGH in October 2021 reported that an estimated 300 to 400 million people globally live with chronic obstructive pulmonary disease. The growing burden of COPD particularly concerns low- and middle-income countries (LMICs) due to increased smoking rates, household- and ambient air pollution, and other exposures, coupled with large and aging populations.

Thus, the increasing number of COPD and asthma cases and the high dependence of the prevalent population on nitric oxide to overcome the symptoms are expected to drive the growth of this segment.

Moreover, an increasing geriatric population globally is boosting the growth of this segment. For instance, the United Nations reported that in the year 2022, there were 771 million people aged 65 years or over globally. The older population is projected to reach 994 million by 2030 and 1.6 billion by 2050. Since asthma is a widely prevalent disease found in people over the age of 65, the growing geriatric population in the segment is expected to drive its growth.

Similarly, a report published by the Global Initiative for Chronic Obstructive Lung Disease in 2022, stated that the prevalence and burden of COPD are projected to increase shortly due to continued exposure to COPD risk factors, a rise in the incidence of interstitial lung diseases, and aging population across the world. This will likely boost the demand and market for inhaled nitric oxide.

North America Region is Expected to Witness a Significant Growth Over the Forecast Period.

North America is expected to witness significant growth over the forecast period. This growth can be attributed to the rising incidence of diseases such as COPD and asthma, the aging population, increasing research and development activities, and the presence of key market players.

There has been a rise in the prevalence of disorders such as neonatal respiratory disorder, tuberculosis, and ARDS. For instance, in March 2022, the Government of Canada reported 4.7 active TB cases per 100,000 persons. The corresponding rate for females was 4.2 cases per 100,000, compared to 5.1 cases per 100,000 for men.

Similarly, an article published by Scientific Reports in August 2022 reported that in Canada, 3.8 million people were living with asthma during the COVID-19 pandemic. Thus, high cases of respiratory disorders are increasing the demand for inhaled nitric oxide, thereby driving the studied market.

Similarly, as per the April 2021 statistics by the Asthma and Allergy Foundation of America, about 20 million adults aged 18 years or above in the United States have asthma. ?Thus, the prevalence of such disorders in the country indicates a consistent demand for inhaled nitric oxide, thereby contributing to the growth of the market studied in the United States.?

Also, new product launches, mergers, acquisition, and other development is boosting the growth of liquid nitric oxide in the studied region. For instance, in September 2022, Mallinckrodt PLC promulgated the submission of a 510(k) premarket notification application to the USFDA for an investigational inhaled nitric oxide delivery system for INOmax (nitric oxide) gas, for inhalation.

INOmax (nitric oxide) gas, for inhalation, is an approved treatment to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (34 weeks gestation), neonates, with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.

Furthermore, the rise in the number of initiatives undertaken by government and non-government organizations is increasing the overall revenue. For instance, in 2021 CDC's NACP provided funds for educating asthma-affected patients. Such initiatives are likely to increase awareness about asthma, which will increase the adoption of inhaled nitric oxide in overcoming the symptoms of asthma, thereby driving the growth of the studied market in the region.

Key Topics Covered:

1 INTRODUCTION

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Respiratory and Other Associated Diseases
4.2.2 Ongoing Research and Development Activities
4.3 Market Restraints
4.3.1 Strict Application Norms across Various Regions
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Product Type
5.1.1 Gas
5.1.2 Delivery Systems
5.2 By Application
5.2.1 Neonatal Respiratory Treatment
5.2.2 Asthma and COPD
5.2.3 Acute Respiratory Distress Syndrome
5.2.4 Malaria Treatment
5.2.5 Tuberculosis Treatment
5.2.6 Other Applications
5.3 Geography

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

For more information about this report visit www.researchandmarkets.com/r/qw8sbn

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]
 
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
 
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

Cision

Cision

View original content:www.prnewswire.com/news-releases/global-inhaled-nitric-oxide-market-report-2023-rising-prevalence-of-respiratory-and-other-associated-diseases-drives-growth-301841304.html

SOURCE Research and Markets

Source link

Metapneumovirus causes many of the same symptoms as COVID 19 such as a bad cough, fever and a possible lung infection.

Article content

A mix of respiratory viruses continue to circulate in B.C., such as respiratory syncytial virus and the virus that cause COVID-19.

Advertisement 2

Article content

But health experts say there’s another virus that may cause similar symptoms as COVID.

Article content

It’s called the human metapneumovirus (HMPV,) and while for most people symptoms will be mild, it can also cause a lung infection, severe cough, sore throat and fever, much like the coronavirus. U.S. health authorities have said that hospitalized cases of HMPV spiked this spring, especially among children, seniors and those with weak immune systems.

But is that happening in B.C.? Here’s what health officials say:

What is human metapneumovirus?

HMPV is a respiratory syncytial virus and most people who are infected experience mild symptoms similar to a cold, according to the Centers for Disease Control and Prevention (CDC). The symptoms last a week, and go away without treatment in healthy individuals. More serious cases can lead to lung infection and severe cough. The CDC says it’s spread through close contact, coughing and sneezing, and is more common in winter and spring.

Article content

Advertisement 3

Article content

It can cause upper and lower respiratory disease in people of all ages, especially young children, older adults and those with weakened immune systems.

HMPV is in the Pneumoviridae family along with respiratory syncytial virus (RSV), and was discovered in 2001, according to the B.C. CDC.

Symptoms include cough, fever, nasal congestion and shortness of breath. Clinical symptoms can progress to bronchitis or pneumonia.

Are there cases of it in B.C.?

Yes.

Since the start of March, 7,990 samples have been tested in B.C., with 510 detections of the virus, according to the B.C. CDC.

The positivity rate in early spring was about 10 per cent and has since declined to below five per cent as of Thursday. The agency said the rates are much lower than COVID.

Advertisement 4

Article content

How do I treat it?

Currently, there’s no vaccine for HMPV or antiviral drugs so doctors focus on treating the patients’ symptoms. The B.C. CDC says people can help prevent the spread of the virus by washing hands, and avoiding contact with people who are sick.

What should people do if they think they have it?

People who have cold-like symptoms should practise respiratory etiquette (coughing and sneezing into a tissue or your elbow) and wash their hands frequently and properly. They’re asked to stay home from work or school, not to share cups and utensils, and to refrain from kissing.

Those who have difficulty breathing or a severe cough that won’t go away should see a doctor.

[email protected]


Spring subscription sale: Our in-depth journalism is possible thanks to the support of our subscribers. For a limited time, you can get full online access to the Vancouver Sun and The Province, along with the National Post and 13 other Canadian news sites, for just $40 for one year or $1 a week for 52 weeks. Support our journalism by subscribing today: The Vancouver Sun.

Comments

Postmedia is committed to maintaining a lively but civil forum for discussion and encourage all readers to share their views on our articles. Comments may take up to an hour for moderation before appearing on the site. We ask you to keep your comments relevant and respectful. We have enabled email notifications—you will now receive an email if you receive a reply to your comment, there is an update to a comment thread you follow or if a user you follow comments. Visit our Community Guidelines for more information and details on how to adjust your email settings.

Join the Conversation

Advertisement 1

Source link

SciCheck Digest

Ventilators can be lifesaving for critically ill COVID-19 patients. A social media claim that a new study shows ventilators killed “nearly all” COVID-19 patients is “quite wrong,” according to the study’s co-author. Ventilator-associated complications can contribute to deaths, but patients are typically put on ventilators when they would otherwise die.


Full Story

COVID-19 can cause lung damage and respiratory failure. In patients who are unable to breathe well enough to supply oxygen to their bodies, mechanical ventilators can be lifesaving and give them time to recover. Ventilators help people breathe by pushing air into their lungs via a tube inserted down their windpipe.

Yet, social media posts have shared an article from the People’s Voice with a false headline: “Official Report: Ventilators Killed Nearly ALL COVID Patients.” The People’s Voice, formerly News Punch, frequently publishes articles with false and inflammatory headlines.

The posts misrepresent the conclusions of a study published in April in the Journal of Clinical Investigation. The idea that ventilators — and not COVID-19 — killed nearly all COVID-19 patients is “quite wrong,” study co-author Dr. Benjamin Singer, a pulmonary and critical care physician at Northwestern Medicine, told us.

Rep. Thomas Massie, a Republican from Kentucky, also misrepresented the conclusions of the study, tweeting, “How many COVID patients died due to the use of ventilators? A recent examination of the data suggests quite a few.”

The idea that ventilators are dangerous, and not COVID-19, is a misinterpretation of his data, Singer said. “It’s not the ventilator that was the cause of death,” he said. “The ventilator was very much life support for these patients. It was ultimately COVID-19” that caused the deaths.

Singer’s study looked at 585 people put on ventilators due to respiratory failure between 2018 and 2022 at Northwestern Memorial Hospital. These people primarily had COVID-19 or some other infectious disease, such as another viral or bacterial illness.

Around half of these very sick patients who required mechanical ventilation — people who likely would have died without the intervention — went on to survive their illness. The survival rate was similar whether they had COVID-19 or another disease and was consistent with the survival rate for COVID-19 patients on ventilators found in another, larger study.

Singer’s study explored the degree to which a known ventilator-related complication called ventilator-associated pneumonia contributes to death, finding that the complication is more common in people with COVID-19 and, when unresolved, is linked to death. VAP is usually treated with antibiotics.

People with COVID-19 likely have an elevated risk of VAP because they stay on ventilators for longer-than-average periods. COVID-19 also affects the immune system and damages the surface of the lungs in unique ways, Singer said, which could potentially make the lungs more susceptible to secondary infections.

VAP contributes to death in some COVID-19 and other infectious disease patients, explained Dr. Mark Metersky, a pulmonary and critical care physician and professor at the University of Connecticut School of Medicine who was not involved in the study.

However, virtually all of these patients would have died if they had not been put on a ventilator, he said. “It’s not that the ventilator killed them, the ones who died. It’s that the ventilator failed to save them.”

A related claim in a popular post — that medical professionals put patients on ventilators due to financial incentives — is also unsupported by evidence, as we and other fact-checkers previously explained. It’s standard for hospitals to get more money for patients, such as those on ventilators, who require more care.

Study Explored Ventilator-Related Pneumonia

VAP typically occurs as a form of secondary pneumonia, which means it shows up in patients who already have another pneumonia diagnosis, such as pneumonia resulting from COVID-19, the flu or a bacterial infection.

People are diagnosed with pneumonia when their lungs become swollen with fluid from a respiratory infection. VAP typically arises from bacteria introduced to the lungs via the patient’s breathing tube.

Singer’s new paper finds that once very sick COVID-19 patients are on ventilators, they are at greater risk of VAP compared with other similarly ill pneumonia patients, he said.

Further, the paper found that “whether that ventilator-associated pneumonia was cured or not was a major determinant of whether patients went on to live or die in the ICU,” he said. However, just being diagnosed with VAP was not associated with a higher risk of death.

Based on these conclusions, the People’s Voice article makes a false claim, which was shared widely: “Nearly all COVID-19 patients who died in hospital during the early phase of the pandemic were killed as a direct result of being put on a ventilator, a disturbing new report has concluded.”

First, many hospitalized COVID-19 patients have died who never went on ventilators. And Singer’s study was not limited to “the early phase of the pandemic” but rather went through March 2022.

As we’ve said, this line of thinking is also misleading because it does not make it clear that the patients on ventilators would have typically died without them. It is also untrue that Singer’s study showed that ventilator-related complications killed “nearly all” ventilated patients who died.

The People’s Voice article explains its reasoning by saying that “most patients” put on ventilators because of COVID-19 developed VAP. “So while COVID-19 may have put these patients in the hospital, it was actually a secondary infection brought on by the use of a mechanical ventilator that caused their deaths,” the article says.

In reality, 57% of COVID-19 patients on ventilators in the study developed VAP and a quarter of other ventilated pneumonia patients did. Around half of all patients with VAP died, which was “not significantly different” from the death rate in patients on ventilators who didn’t have VAP, according to the study.

Singer and his colleagues did find that patients whose VAP was not successfully treated were more likely to die than patients whose VAP resolved, indicating a connection between VAP and poor outcomes. The study was not randomized, and the researchers write that they cannot definitively determine that unresolved VAP — and not some other factor associated with it — leads to poor outcomes.

Metersky was skeptical that VAP is that much of a contributor to mortality, pointing to other studies that show a lower rate of VAP in pneumonia patients than was found in Singer’s study.

“Yes, some patients who are put on a ventilator will develop a fatal complication,” Metersky said. “Probably 1 in 100” patients put on a ventilator develop fatal VAP, he said, based on data from before the pandemic. Since about twice as many COVID-19 patients develop VAP compared with other pneumonia patients on ventilators, he said that would indicate that around 2% of people with COVID-19 who go on a ventilator die of VAP.

“But there are other complications,” Metersky said. These can include damage to the lungs from high oxygen and the air pressure from the ventilator or side effects from drugs used to sedate people on ventilators, for instance. “That’s why we don’t put a patient on a ventilator unless they absolutely need it,” he said.

Regardless, “it’s ridiculous to go from that study to say that the ventilators are killing all these people,” Metersky said, referring to the claim that nearly all COVID-19 deaths were caused by ventilators.

Early Ventilation Did Not Cause Mass Deaths

Other false claims, reviewed previously by others, state that overuse of ventilators played a major role in the first wave of COVID-19 deaths.

There were some suggestions very early in the pandemic that doctors should put COVID-19 patients on ventilators earlier than other pneumonia patients, Singer and Metersky both said, out of concern that respiratory failure might progress very quickly. 

This was soon followed by calls for caution in ventilating patients early, and these practices quickly stopped, Singer said. “The standard indications for initiation of mechanical ventilation are really the same as they always have been” for patients with pneumonia, he said, regardless of whether they have COVID-19.

Multiple facts about the early ventilation recommendations are unclear. First, there was no standard definition of what experts meant when recommending “early” ventilation. Decisions on when patients require mechanical ventilation are based on the best judgment of their doctors as they monitor multiple indicators. Doctors want to be sure the ventilator is truly necessary — that the patient is headed toward death from respiratory failure without it. But they also don’t want to wait until the patient has organ damage from lack of oxygen.

Second, it’s unclear how widespread early ventilation was. Singer mentioned that his own recent paper showed that Northwestern Medicine put patients with COVID-19 on ventilators after a similar amount of time in the ICU as other pneumonia patients. Others have pointed out that some doctors at the beginning of the pandemic took measures to avoid putting patients on ventilators due to shortages.

Finally, it’s uncertain what impact early ventilation had on patients. The available research, recently reviewed in a blog post by epidemiologist Gideon Meyerowitz-Katz, a Ph.D. candidate at the University of Wollongong in Australia, indicates that early versus later ventilation did not appreciably affect COVID-19 deaths. For instance, a review study that pooled and analyzed data from multiple studies found that going on a ventilator within a day of entering the ICU versus later had no impact on mortality.

It is possible that people occasionally were put on ventilators who could have avoided them, but this is difficult to quantify.

“There were probably a small number of patients who got put on a ventilator who ultimately might not have needed it,” Metersky said. “As we learned more about the disease, we learned to recognize that some patients may not need the ventilator. But it wasn’t this big conspiracy that we put everyone on the ventilator even though they could have gone home instead.”

Editor’s note: SciCheck’s articles providing accurate health information and correcting health misinformation are made possible by a grant from the Robert Wood Johnson Foundation. The foundation has no control over FactCheck.org’s editorial decisions, and the views expressed in our articles do not necessarily reflect the views of the foundation.

Sources

Pulmonary Manifestations.” COVID-19 Real-Time Learning Network. Updated 22 Feb 2022.

Tobin, Martin and Manthous, Constantine. “Mechanical Ventilation.” American Journal of Respiratory and Critical Care Medicine. Published 15 Jul 2017. Updated April 2020.

Adl-Tabatabai, Sean. “Official Report: Ventilators Killed Nearly ALL COVID Patients.” The People’s Voice. 13 May 2023.

Jones, Brea. “Posts Fabricate Charge Against Bill Gates in Philippines.” FactCheck.org. 10 Mar 2023.

Spencer, Saranac Hale. “Hate Crimes Hotline Headline Is Wrong.” FactCheck.org. 30 Nov 2018.

Yandell, Kate. “Posts Share Fake Chelsea Clinton Quote About Global Childhood Vaccination Effort.” FactCheck.org. 10 May 2023.

Gao, Catherine A. et al. “Machine Learning Links Unresolving Secondary Pneumonia to Mortality in Patients with Severe Pneumonia, Including COVID-19.” The Journal of Clinical Investigation. 27 Apr 2023.

Massie, Thomas (@RepThomasMassie). “How many COVID patients died due to the use of ventilators? A recent examination of the data suggests quite a few. ‘The investigators found nearly half of patients with COVID-19 develop a secondary ventilator-associated bacterial pneumonia.’” Twitter. 15 May 2023.

Nolan, Margaret B. et al. “Mortality Rates by Age Group and Intubation Status in Hospitalized Adult Patients From 21 United States Hospital Systems During Three Surges of the COVID-19 Pandemic.” Chest. 29 Jan 2023.

Frequently Asked Questions about Ventilator-Associated Pneumonia.” CDC website. Updated 9 May 2019.

Adele – Conspiracy Queen ???? (@truth.bomb.mom). “Such a bummer that this happened ????.” Instagram. 21 May 2023.

Fichera, Angelo. “Hospital Payments and the COVID-19 Death Count.” FactCheck.org. 21 Apr 2020.

Kertscher, Tom. “Fact-Check: Hospitals and COVID-19 Payments.” PolitiFact. 21 Apr 2020.

Pneumonia – Causes and Risk Factors.” NIH website. Updated 24 March 2022.

Pneumonia – What Is Pneumonia?” NIH website. Updated 24 Mar 2022.

Kohbodi, GoleNaz A. et al. “Ventilator-Associated Pneumonia.” Updated 10 Sep 2022.

Metersky, Mark L. et al. “Trend in Ventilator-Associated Pneumonia Rates Between 2005 and 2013.” JAMA. 13 Dec 2016.

Melsen, Wilhelmina G., et al. “Attributable Mortality of Ventilator-Associated Pneumonia: A Meta-Analysis of Individual Patient Data from Randomised Prevention Studies.” Lancet Infectious Diseases. 25 Apr 2013.

Metersky, Mark L. et al. “Temporal Trends in Postoperative and Ventilator-Associated Pneumonia in the United States.” Infection Control and Hospital Epidemiology. 3 Nov 2022.

Meyerowitz-Katz, Gideon. “Did Ventilators Kill People During COVID-19?” Medium. 25 May 2023.

Howard, Jonathan. “Intubations and Accusations: Doctors Were ‘Just Going Crazy, and Intubating People Who Did Not Have to Be Intubated.’” Science-Based Medicine. 19 Sep 2021.

Tobin, Martin J. et al. “Caution about Early Intubation and Mechanical Ventilation in COVID-19.” Annals of Intensive Care. 9 Jun 2020.

Anesi, George L. “COVID-19: Respiratory care of the nonintubated hypoxemic adult (supplemental oxygen, noninvasive ventilation, and intubation).” UpToDate. Updated 22 May 2023.

Marino, Ryan (@RyanMarino). “And -anecdotally- I was treating COVID patients in 2020. It was bleak and terrifying. They were incredibly sick and we actually did not have enough ventilators as we needed for this disease. I still remember the panicky feeling of using every possible attempt to avoid intubation.” Twitter. 15 May 2023.

Mansfield, Erin. “As the Coronavirus Curve Flattened, Even Hard-Hit New York Had Enough Ventilators.” USA Today. 28 Apr 2020.

Papoutsi, Eleni et al. “Effect of Timing of Intubation on Clinical Outcomes of Critically Ill Patients with COVID-19: A Systematic Review and Meta-Analysis of Non-Randomized Cohort Studies.” Critical Care. 25 Mar 2021.



Source link

Fingal County Council has been awarded a Gold Medal at this year’s Bord Bia Bloom festival for its remarkable show garden, “A Breathing Space for Fingal.”

This large-scale garden showcases its stunning collection of more than 3,000 perennial plants and mature trees, creating a forest bathing space within the grounds of Bord Bia Bloom.

Designed by the talented Jane McCorkell, “A Breathing Space for Fingal” showcases the invaluable contribution of well-designed open spaces to the overall liveability of our villages, towns, and cities.

This exceptional garden underscores the importance of incorporating nature into our everyday lives.

One of the remarkable aspects of this garden is its commitment to sustainability.

Nearly all construction materials used in its creation were recycled or upcycled from old materials sourced from Fingal County Council’s store yards.

This innovative approach highlights the council’s dedication to environmental conservation and its vision for a more sustainable future.

Mayor of Fingal, Cllr Howard Mahony, expressed his delight at the recognition: “We are incredibly proud to have received the gold medal at Bord Bia Bloom 2023. This remarkable garden reflects our commitment to creating sustainable and inclusive spaces that enhance the wellbeing of our communities.”

Following the conclusion of the Bloom festival, “A Breathing Space for Fingal” will find a permanent home as part of a Community Garden located in Lanesborough Park, Meakstown in Dublin 15.

The garden will also serve as a lasting tribute the people who endured hardships during the challenging period of the Covid-19 pandemic, reminding us of the importance of resilience and the healing power of nature.

Kevin Halpenny, Senior Parks & Landscape Officer at Fingal said: “The garden’s focal point is the carefully curated selection of trees, representing a diverse range of species.

“Trees of varying heights, including multi-stem Cornus, birch, pine, bird cherry, and beech, all of which have been thoughtfully chosen to imitate the dense canopy found in natural forests.

“The arrangement of these trees creates a serene and peaceful atmosphere, inviting visitors to explore and unwind amidst the beauty of nature.”

For more information about “A Breathing Space for Fingal” please visit: www.fingal.ie/breathing-space-fingal-county-council-bloom-2023

Source link

by Xinhua writer Tan Jingjing

LOS ANGELES, June 2 (Xinhua) -- As cases of COVID-19, flu and respiratory syncytial virus (RSV) were winding down across the United States, infections of another respiratory virus, called human metapneumovirus (HMPV), were picking up during spring and drawing concern as many people had not known about it.

Discovered in 2001, HMPV is in the Pneumoviridae family along with RSV. Broader use of molecular diagnostic testing has increased identification and awareness of HMPV as an important cause of upper and lower respiratory infection, according to the U.S. Centers for Disease Control and Prevention (CDC).

Cases of HMPV spiked in the United States this spring, according to the CDC's respiratory virus surveillance system. The percent of tests positive for HMPV surged to 17.5 percent for antigen tests and 9.6 percent for PCR tests at the end of March.

At its peak in mid-March, nearly 11 percent of tested specimens were positive for HMPV, a number that was about 36 percent higher than the average, pre-pandemic seasonal peak of 7 percent test positivity, according to a CNN report.

It filled hospital intensive care units with young children and seniors who are the most vulnerable to these infections.

HMPV can cause upper and lower respiratory disease in people of all ages, especially among young children, older adults, and people with weakened immune systems, according to the CDC.

Surveillance data from the CDC's the National Respiratory and Enteric Virus Surveillance System shows HMPV to be most active during late winter and spring in temperate climates.

Symptoms commonly associated with HMPV include cough, fever, nasal congestion, and shortness of breath, according to the CDC.

Unlike COVID-19 and the flu, there is no vaccine for HMPV or antiviral drugs to treat it. Instead, doctors care for seriously ill people by tending to their symptoms.

But there is no need to be too concerned about HMPV, a leading epidemiologist told Xinhua.

"The transmission mode, prevention methods, symptoms, and treatment of this virus are similar to influenza. So there is no need to worry too much except for the elderly people, the immunocompromised population and other high-risk groups," Zhang Zuofeng, professor and chair of the Department of Epidemiology at the University of California, Los Angeles, told Xinhua on Friday. Enditem

Source link